Curemark Medi Sciences Private Limited
About Curemark Medi Sciences Private Limited
Data last updated:
Curemark Medi Sciences Private Limited is a private limited company based in Hubli, Karnataka, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 12 March 2018 and has been in existence for over 8 years.
The company is registered with the Registrar of Companies (ROC), Bangalore, under CIN U74999KA2018PTC111014. Its GSTIN is 29AAHCC4535E1ZP (Karnataka).
The company has an authorised share capital of ₹10 Lakh and a paid-up capital of ₹1 Lakh. It is led by directors including Umesh Naganagoud Hotagigoudr (Managing Director) and Pradeep Hodaghatta Puttaraju.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Hubli, Karnataka.
As per the financials filed for FY 2025, the company reported a revenue of ₹1.65 Cr, a decline of 10% compared to the previous year. For the same year it recorded a net loss of ₹2.87 Lakh (net margin -1.7%) and EBITDA of ₹7.59 Lakh (EBITDA margin 4.6%). Revenue has grown at a compounded annual rate (CAGR) of 2% over three years and 13% over five years.
The company is associated with 1 brand: CureMarkMediSciences. As per MCA filings, the company has open charges of ₹9.9 Lakh on record.
Company details
Contact details
Curemark Medi Sciences Private Limited's registered office is in Hubli, Karnataka. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Registered AddressCts No. 4911/28 # 1 Aroodha Neralu Gr Floor Lothimath Layout Heggeri Road Old Hubl, I, Hubli, Karnataka, India – 580024
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Curemark Medi Sciences Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Brands
Curemark Medi Sciences operates one associated brand: CureMarkMediSciences. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Develops and distributes quality pharmaceutical products for various medical needs worldwide. | curemarkmedisciences.com |
Business activity
The main business activity of Curemark Medi Sciences is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Curemark Medi Sciences Private Limited, buy the company report.
Financials of Curemark Medi Sciences Private Limited
FY 2025 filings availableCuremark Medi Sciences Private Limited reported revenue of ₹1.65 Cr (down 10% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR)
Revenue fell 10% in the latest year, but over five years it has grown at a compounded annual rate (CAGR) of 13%. EBITDA rose 744% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹7.59 Lakh | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | -₹2.87 Lakh | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 4.6% | ||||
| Net Profit Margin | -1.7% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Curemark Medi Sciences Private Limited, buy the company report.
Board of directors of Curemark Medi Sciences Private Limited
Curemark Medi Sciences has 4 directors on record. No former directors are listed.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Pradeep Hodaghatta Puttaraju | Director | 01 Oct 2020 | 6 Years 0 Months | Current |
| Umesh Naganagoud Hotagigoudr | Managing Director | 12 Mar 2018 | 8 Years 7 Months | Current |
| Pallavi Umesh Hotagigouder | Director | 12 Mar 2018 | 8 Years 7 Months | Current |
| Sukesha Manjupoojari | Director | 12 Mar 2018 | 8 Years 7 Months | Current |
Peer comparison
Curemark Medi Sciences Private Limited is compared with the 10 companies closest to it by revenue in the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Petrochem India Private Limited | ₹1.66 Cr (FY 2025) | -3.0% | Kanpur, Uttar Pradesh, India | |||
| Sri Chavadi Pharma Private Limited | ₹1.66 Cr (FY 2025) | 115.0% | Kottur, Andhra Pradesh, Telangana, India | |||
| Kenn Pharmaceuticals Private Limited | ₹1.65 Cr (FY 2024) | 7.0% | Chandigarh, India | |||
| Noburu Chemicals Private Limited | ₹1.65 Cr (FY 2025) | -29.0% | Vadodara, Gujarat, India | |||
| MRG Biotech Private Limited | ₹1.65 Cr (FY 2019) | 8.0% | Karnal, Haryana, India | |||
| Curemark Medi Sciences Private Limitedthis company | ₹1.65 Cr (FY 2025) | -₹2.87 Lakh | -1.7% | -10.0% | Hubli, Karnataka, India | |
| Nikhil Intermediates Pvt Ltd | ₹1.65 Cr (FY 2025) | 118.0% | Ahmedabad, Gujarat, India | |||
| Vistony India Private Limited | ₹1.65 Cr (FY 2025) | 2646.0% | Tijara, Rajasthan, India | |||
| Sapnix Biocare Private Limited | ₹1.65 Cr (FY 2024) | -13.0% | Delhi, India | |||
| Sarv Tech Private Limited | ₹1.65 Cr (FY 2025) | 12.0% | Delhi, India | |||
| Praetor Pharmaceuticals Private Limited | ₹1.65 Cr (FY 2025) | 18.0% | Bairi Gaon, Uttar Pradesh, India |
To see the full peer comparison of Curemark Medi Sciences Private Limited, buy the company report.
Auditor
Curemark Medi Sciences Private Limited is audited by BASAVARAJ SATYANARAYANAPPA KOPARDE for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| BASAVARAJ SATYANARAYANAPPA KOPARDE | FY 2023 | 215799 |
Shareholding
The shareholding of Curemark Medi Sciences Private Limited is on record for 5 financial years, the latest being FY 2023, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Curemark Medi Sciences Private Limited, buy the company report.
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 11 Aug 2020 | 100360494 | Others | ₹9.9 Lakh | Open |
Total charge records: 1 View all charges
Legal cases
No court or tribunal cases involving Curemark Medi Sciences Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Curemark Medi Sciences Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
Curemark Medi Sciences has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 29AAHCC4535E1ZP | Karnataka | Active | 22 May 2018 |
To see the full GST registrations and return filing status of Curemark Medi Sciences Private Limited, buy the company report.
Recent activity
Curemark Medi Sciences Private Limited has 4 board changes on record since 2018: 4 appointments. The latest: Pradeep Hodaghatta Puttaraju was appointed as Director on 01 Oct 2020.
Frequently asked questions
Curemark Medi Sciences is an active private limited company based in Hubli, Karnataka, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 12 March 2018 (8+ years old) and is registered under CIN U74999KA2018PTC111014.
Curemark Medi Sciences has 4 current directors:
- Umesh Naganagoud Hotagigoudr - Managing Director
- Pradeep Hodaghatta Puttaraju - Director
- Pallavi Umesh Hotagigouder - Director
- Sukesha Manjupoojari - Director
The latest financial statements of Curemark Medi Sciences on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 September 2025. Year-wise statements from FY 2018 are in the company report.
The GSTIN of Curemark Medi Sciences is 29AAHCC4535E1ZP, registered in Karnataka.
The CIN (Corporate Identification Number) of Curemark Medi Sciences is U74999KA2018PTC111014. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Curemark Medi Sciences was incorporated on 12 March 2018, making it 8+ years old. It is registered with the Registrar of Companies, Bangalore.
The peers of Curemark Medi Sciences by revenue are Petrochem India Private Limited, Sri Chavadi Pharma Private Limited, Kenn Pharmaceuticals Private Limited, Noburu Chemicals Private Limited, MRG Biotech Private Limited and 5 more, all in the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Pradeep Hodaghatta Puttaraju was appointed as Director on 01 Oct 2020. Pallavi Umesh Hotagigouder was appointed as Director on 12 Mar 2018. Sukesha Manjupoojari was appointed as Director on 12 Mar 2018. Curemark Medi Sciences has 4 board changes on record in total.
The registered office of Curemark Medi Sciences is at Cts No. 491128 # 1 Aroodha Neralu Gr Floor Lothimath Layout Heggeri Road Old Hubl, I, Hubli, Karnataka, India – 580024.
Curemark Medi Sciences operates in the pharma industry, in the drug formulation and development segment.
Curemark Medi Sciences has open charges of ₹9.9 Lakh and no satisfied charges on record as per latest MCA filings.